NovoCure (NASDAQ:NVCR) Announces Quarterly Earnings Results

Posted by on Oct 31st, 2026

NovoCure (NASDAQ:NVCR – Get Free Report) issued its earnings results on Thursday. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.14, FiscalAI reports. NovoCure had a negative net margin of 16.78% and a negative return on equity of 36.18%. The firm had revenue of $193.40 million for the quarter, compared to the consensus estimate of $182.28 million. During the same quarter in the prior year, the firm posted ($0.33) earnings per share. The business’s revenue was up 15.7% on a year-over-year basis.

Here are the key takeaways from NovoCure’s conference call:

  • Q3 net revenue rose 16% year over year to $193 million, driven by 19% growth in active patients, stronger Optune Gio performance, and contributions from Optune Lua and Optune Pax. The company raised its 2026 revenue guidance to $736 million–$743 million.
  • Optune Gio active patients reached a record 4,729, up 11% year over year, while Optune Lua’s Japan launch gained momentum with 110 Japanese patients and $4 million in quarterly revenue. Management expects Japan to become NovoCure’s second-largest market behind the U.S.
  • The Optune Pax launch faced significant U.S. headwinds after the introduction of daraxonrasib, with practices reportedly overwhelmed by reimbursement appeals and treatment-related skin irritation; Pax ended the quarter with 276 active patients and $3.7 million in revenue. NovoCure expects to rebuild momentum through improved commercial execution, NCCN guideline inclusion, and planned combination studies with KRAS inhibitors.
  • Profitability metrics improved substantially, with adjusted EBITDA of $16 million versus negative $3 million a year earlier and updated full-year adjusted EBITDA guidance of $24 million–$34 million. Management cautioned that quarterly results may fluctuate, but said its next objective is cash-flow breakeven.
  • The FDA is reviewing the Optune Mya application for brain metastases from non-small cell lung cancer, with a decision expected by year-end and a potential early-2027 launch. KEYNOTE-D58 enrollment remains on track for completion by year-end, supporting potential future GBM growth.

NovoCure Stock Performance

Shares of NVCR stock traded up $0.04 during trading hours on Friday, reaching $13.15. The company had a trading volume of 1,974,507 shares, compared to its average volume of 1,964,834. The business has a fifty day moving average price of $15.79 and a 200-day moving average price of $14.79. NovoCure has a one year low of $9.82 and a one year high of $21.45. The firm has a market cap of $1.53 billion, a PE ratio of -12.41 and a beta of 0.99. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.70 and a current ratio of 2.89.

NovoCure News Roundup

Here are the key news stories impacting NovoCure this week:

  • Positive Sentiment: NovoCure reported third-quarter revenue of $193.4 million, up 15.7% year over year and above the $182.3 million analyst consensus. Its adjusted loss of $0.09 per share was substantially narrower than the expected $0.23 loss and the year-ago loss of $0.33. NovoCure Shares Fall After Narrower Q3 Loss, Revenue Beat
  • Positive Sentiment: Management raised its 2026 guidance, reinforcing expectations for continued revenue growth and improved financial performance. The earnings call also provided additional detail on the company’s commercial and clinical strategy. NovoCure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
  • Positive Sentiment: NovoCure entered a clinical-trial collaboration and supply agreement with Verastem Oncology to evaluate Tumor Treating Fields therapy alongside VS-7375 for pancreatic cancer. The partnership could expand the company’s pipeline and future indications. NovoCure and Verastem Collaboration
  • Neutral Sentiment: Despite the earnings beat, NovoCure remains unprofitable, with a negative net margin and return on equity. Investors therefore remain focused on whether higher revenue and raised guidance can translate into sustainable profitability. NovoCure Third-Quarter Results
  • Negative Sentiment: NovoCure’s CEO said adoption of the Optune Pax system was slowed by competition from Revolution Medicines’ daraxonrasib. Wedbush characterized the issue as a disruption rather than direct competition, but the slower adoption raises concerns about near-term commercial momentum. Optune Pax Adoption Commentary
  • Negative Sentiment: Wells Fargo lowered its price target for NVCR from $20 to $15 and maintained an “equal weight” rating. Although the new target implies upside, the sharp reduction signals reduced confidence in the stock’s near-term risk-reward profile. Wells Fargo NovoCure Rating

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wedbush boosted their price objective on shares of NovoCure from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Zacks Research upgraded NovoCure from a “strong sell” rating to a “hold” rating in a research note on Friday, July 24th. Wells Fargo & Company reduced their target price on NovoCure from $20.00 to $15.00 and set an “equal weight” rating for the company in a report on Friday. Weiss Ratings lowered NovoCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Finally, HC Wainwright set a $32.00 price target on NovoCure in a research note on Friday, July 24th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, NovoCure has a consensus rating of “Hold” and an average price target of $20.80.

Read Our Latest Stock Report on NVCR

NovoCure Company Profile

(Get Free Report)

NovoCure Ltd. (NASDAQ: NVCR) is an oncology company that develops and commercializes therapies based on Tumor Treating Fields (TTFields), low-intensity electric fields designed to disrupt the division of cancer cells. Its treatments are delivered through portable, wearable devices used alongside other cancer therapies.

The company’s principal products include Optune Gio for certain adults with glioblastoma and Optune Lua for adults with unresectable, locally advanced or metastatic pleural mesothelioma and certain forms of metastatic non-small cell lung cancer.

Read More

Earnings History for NovoCure (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.